Multiple myeloma (MM) is a plasma cell malignancy. The minichromosome maintenance (MCM) family involve in DNA replication and is vital in limiting replication in cell cycle. The prognostic role of MCMs in MM is still unclear. We took four independent GEO datasets to analyze the relationship between the expression of MCMs and myeloma progression and survival. The expression of MCMs showed an upward trend with myeloma progression in 205 patients. High MCM2/3/4/6/8 expression was associated with both poor EFS and OS (all p < 0.050). Multivariate analysis demonstrated that high MCM2 expression, B2M, and LDH were independent risk factors. Moreover, the combination of MCM2/B2M and MCM2/LDH was a better tool in prognostication. In conclusion, high MCM2 expression is an independent adverse prognostic factor and could be used as a prognostic biomarker in MM.

中文翻译：

---

微染色体维持家族在多发性骨髓瘤中的预后作用。

多发性骨髓瘤 (MM) 是一种浆细胞恶性肿瘤。微染色体维持 (MCM) 家族参与 DNA 复制，对限制细胞周期复制至关重要。MCMs 在 MM 中的预后作用仍不清楚。我们采用四个独立的 GEO 数据集来分析 MCM 的表达与骨髓瘤进展和生存之间的关系。205 名患者的 MCMs 表达随骨髓瘤进展呈上升趋势。高 MCM2/3/4/6/8 表达与较差的 EFS 和 OS 相关（所有 p < 0.050）。多变量分析表明，高 MCM2 表达、B2M 和 LDH 是独立的危险因素。此外，MCM2/B2M 和 MCM2/LDH 的组合是更好的预测工具。综上所述，